 SAN FRANCISCO, Aug. 11, 2021 GLOBE NEWSWIRE -- FibroGen, Inc. NASDAQ: FGEN today announced that the U.S. Food and Drug Administration FDA has issued a complete response letter regarding the New Drug Application NDA for roxadustat for the treatment of anemia of chronic kidney disease CKD. 